CATX · CIK 728387
What Perspective Therapeutics, Inc. told the SEC could break it.
Perspective's alpha-particle therapy business has acute single points of failure in its supply chain: it obtains nearly all its Thorium-228 — the precursor to the 212Pb isotope its treatments rely on — solely from the U.S. Department of Energy, with one vendor making its chromatography columns and one vendor assembling and loading isotopes into its generators. That fragile supply sits under a pre-revenue company: since the 2023 Isoray/Viewpoint merger it has focused on R&D for programs like VMT-α-NET and VMT01, generates no product revenue beyond a discontinued brachytherapy business, and has incurred significant losses, leaving it dependent on equity raises. And because some of its vendors and suppliers are abroad, shifts in U.S. trade policy — import restrictions and higher tariffs — could disrupt its supply and raise costs.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Sole-source dependency
- Single-source supply of Thorium-228 (DOE) and single vendors for generator componentshigh
Perspective relies on single vendors across its alpha-particle therapy supply chain — nearly all Thorium-228 (212Pb precursor) comes solely from the DOE, with one vendor making resin chromatography columns and one vendor assembling/loading isotopes into its 212Pb generators — concentrating critical single points of failure.
“We rely on single vendors to provide supplies and services used in the development and production of our alpha-particle therapies. We obtain nearly all our supply of Thorium-228 (a precursor to 212 Pb) from a single supplier, the U.S. Department of Energy (DOE).”
SEC filing →As of 2026
Liquidity & debt
- Pre-revenue clinical-stage company with history of operating lossesmedium
Since the 2023 Isoray/Viewpoint merger, Perspective has focused on R&D for VMT-α-NET, VMT01, PSV359 and other programs, has no product revenue (apart from its discontinued brachytherapy business), and has incurred significant net losses, leaving it dependent on equity raises (ATM, private placements).
“we have engaged primarily in research and development activities related to VMT-α-NET, VMT01, PSV359 and our other programs, have not generated any revenue from product sales other than our discontinued brachytherapy business and have incurred significant net losses.”
SEC filing →As of 2026
Regulatory & policy
- Trade-policy/tariff exposure on foreign vendors and suppliersmedium
Because some of Perspective's vendors, manufacturers and suppliers are in foreign countries, changes in U.S. trade policy — import restrictions, increased tariffs, and altered trade agreements — could disrupt its product supply and raise costs.
“Because some of our vendors, manufactures and suppliers are located in foreign countries, we are exposed to the possibility of product supply disruption and increased costs in the event of changes in the policies, laws, rule”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
U.S. Department of Energy (DOE)
“We obtain nearly all our supply of Thorium-228 (a precursor to 212 Pb) from a single supplier, the U.S. Department of Energy (DOE). In January 2021, we entered into a 10-year contract with the DOE for the purchase of Thorium-228.”
Cited →“On January 8, 2024, we entered into an option agreement (Option Agreement) with Lantheus whereby Lantheus was granted an exclusive option to negotiate an exclusive, worldwide,”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch